The Authority required (Streamlined) listing of denosumab for osteoporosis in women aged ≥ 70 years has changed from 1 August 2012. The required bone mineral density T-score has been changed from ≤ –3.0 to ≤ –2.5. The T-score cut-off is now the same as applies
to alendronate for osteoporosis.
1
The Pharmaceutical Benefits Advisory Committee recommended the change in listing on the basis that, in this patient group, denosumab 60 mg once every 6 months has a similar effect to that of alendronate 70 mg once weekly, at a similar cost.1 Previously denosumab was listed on the basis of a comparison with zoledronic acid.2
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.
